SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SIBIA Neurosciences (SIBI) -- Ignore unavailable to you. Want to Upgrade?


To: scaram(o)uche who wrote (520)8/10/1999 5:18:00 PM
From: aknahow  Respond to of 579
 
IMO the filing reveals a certain amount of weakness on the part of BVF. Another buyer is about the only strong card and it is obvious BVF does not hold this card as of yet. Too difficult to convince others that an undeterminable, future royalty stream has greater value than cash now. Actions speak louder than words and I still believe that as long as the market price remains above $8.5 the tender offer is in trouble. But if BVF is unable to keep buying shares and no one else steps in then I wonder what will keep the price up?



To: scaram(o)uche who wrote (520)8/11/1999 3:09:00 PM
From: RCMac  Read Replies (1) | Respond to of 579
 
Biospace Article today: "So Long Sibia . . . Are Sibia's most important shareholders getting a fair shake?" biospace.com (Thanks, Mike McFarland on "son of T/FIF" thread.)